Nu-Med Plus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
March 30, 2020 at 04:15 pm EDT
Share
Nu-Med Plus, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was USD 1.019 million compared to USD 1.169 million a year ago. Net loss was USD 1.036 million compared to USD 1.188 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago.
Nu-Med Plus, Inc. is a medical device company, which is principally engaged in the designing, development, enhancement and commercialization of later-stage medical devices. The Company is focused on the creation of a nitric oxide generating formulation, a hospital bedside nitric oxide (NO) delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community throughout the world. Hospital NO Unit delivers a continuous intra-breath concentration of therapeutic NO to patients who are on a ventilator in a hospital setting. Clinical Delivery System is a simplified version of the hospital unit. Portable Delivery System delivers high purity NO to the patient at prescribed intervals for 24 hours per day at controlled doses by means of a nasal cannula or a face mask. Reagent Delivery provides a range of concentrations and flow rates of NO.
NU-MED PLUS, INC. 
